A physiologically based pharmacokinetic model for [ 68 Ga]Ga-(HA-)DOTATATE to predict whole-body distribution and tumor sink effects in GEP-NET patients.

Hinke SiebingaBerlinda J de Wit-van der VeenJos H BeijnenThomas P C DorloAlwin D R HuitemaJeroen J M A Hendrikx

Published in: EJNMMI research (2023)

Ga]Ga-HA-DOTATATE were caused by different affinity profiles, while tumor uptake was mainly affected by tumor blood flow and blood volume. Furthermore, tumor sink predictions showed that for the majority of patients a tumor sink effect is not expected to be clinically relevant.

Keyphrases

pet ct
end stage renal disease
blood flow
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
patient reported outcomes
mass spectrometry